Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.45 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28603644 | 0.88 | BAZ2B (0.51) | PTGDR2HDAC1HDAC6PTGER2PTGDR | |
| SCHEMBL28602906 | 0.88 | HDAC1 (0.54) | PTGDR2HPGDSHDAC1HDAC6HTR6 | |
| SCHEMBL5107551 | 0.87 | HDAC1 (0.57) | PTGDR2HDAC1HDAC6PTGER2PTGDR | |
| SCHEMBL31078485 | 0.87 | HDAC1 (0.57) | PTGDR2HDAC1HDAC6PTGER2PTGDR | |
| SCHEMBL5108079 | 0.84 | BAZ2B (0.53) | PTGDR2HPGDSHDAC1HDAC6PTGER2 | |
| SCHEMBL14015618 | 0.83 | PTGDR2 (0.54) | PTGDR2PTGER2PTGDRCYP2C9 | |
| SCHEMBL29034621 | 0.82 | PTGDR2 (0.46) | PTGDR2CYP2C9 | |
| SCHEMBL3090435 | 0.82 | PTGDR2 (0.67) | PTGDR2HDAC1HDAC6PTGER2PTGDR | |
| SCHEMBL10773567 | 0.81 | AKR1B10 (0.52) | PTGDR2 | |
| SCHEMBL10773537 | 0.80 | PTGDR2 (0.50) | PTGDR2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449476-B2 | Tetrahydrocarboline antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449476-B2 | Tetrahydrocarboline antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050267130-A1 | Tetrahydrocarboline antiviral agents | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267130-A1 | Tetrahydrocarboline antiviral agents | CD4, CCR5, HAVCR2 | PTGDR2 1693/4885HPGDS 2328/4885HDAC1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.